Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Largest off-the-shelf diploid KO library, over 2,800 cell lines
Invitae Corporation, a leading medical genetics company, has announced that it has entered into a definitive agreement to acquire Jungla Inc.
A list of the top 10 biotech IPOs from January to the end of June this year shows significant involvement in the Hong Stock exchange, with five companies based in China, and one, Frontage Holdings, operating in both the U.S. and China.
Todos Medical Ltd., a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer’s disease, announced that it has launched a roadshow for a public offering of up to $7,000,000 of units.
Acquired assets from NCARDIA AG include IP portfolio, IPSC-based cellular products and an experienced stem cell biology team
RA Capital Management, LLC announced the first and final closing of its inaugural venture fund, RA Capital Nexus Fund, L.P., at just over $300 million, boosting RA Capital’s private deal capacity to nearly $1 billion and total assets under management to approximately $2.5 billion.
The M&A moves are expected to increase the oncology pipelines of both companies.
vasopharm GmbH, a private biopharmaceutical company developing a novel treatment for traumatic brain injury, announced the successful completion of a €9.5 million financing co-led by HeidelbergCapital Private Equity and EF Investments.
BioArctic received MEUR 15 milestone payment from Eisai for start of BAN2401 confirmatory Phase 3 study in early Alzheimer’s disease
Allergy Therapeutics plc provides a trading update for the year ended 30 June 2019 ahead of its Preliminary Results to be announced on 25 September 2019.